MedTrace Logo

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

NCT01724177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-05-29

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.

Conditions

  • Adult T-Cell Leukemia-Lymphoma

Interventions

DRUG

Lenalidomide

25 mg of Lenalidomide administered orally once daily

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Toru Sasaki · Celgene K.K.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-12
Primary Completion
2014-11-20
Completion
2017-03-21

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01724177 on ClinicalTrials.gov